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Abstract
Background: Process evaluation studies are recommended to improve our understanding of underlying
mechanisms related to clinicians, patients, context and intervention delivery that may impact on trial or program
results and on their potential transferability to practice. This paper aims to document the translation of a type-2
diabetes (T2D) prevention program into the routine context of several primary care centers, assessing process
indicators related to clinician adoption, patient recruitment, exposure to the intervention components and baseline
characteristics.
Methods: An observational descriptive process evaluation study was conducted of the 2.5-year implementation of
the Prevention of Diabetes in Euskadi cluster randomized trial in 14 primary care centers of the Basque Health
Service (Osakidetza). The clinical intervention consisted of three components: (1) risk screening, (2) an educational
intervention promoting healthy lifestyles, and (3) remote support (follow-up). A passive dissemination strategy of
providing training and materials was used to translate the intervention into practice. All non-diabetic patients aged
45 to 70 years who were identified as being at high risk of developing T2D were eligible for study inclusion. The
RE-AIM framework guided the process evaluation.
Results: Overall, 31.4 % of family physicians and 57.6 % of nurses participated in the study, while 4170 out of
67,293 (6.2 %) targeted patients who attended the centers during the implementation period were reached
through the screening. Around half of the screened patients were identified as being at high risk of developing
T2D (FINDRISC score ≥14). The rate of refusal to participate and the proportion of women were higher in the
intervention group. Finally, 634 and 454 non-diabetic 45- to 70-year-old patients who were at high risk of T2D were
included in the control and intervention group centers (intervention reach = 48 %). Significant variability in most
process indicators was observed at center level.
Conclusion: The passive dissemination strategy has produced modest process indicators related to the adoption,
reach and implementation of the intervention program, and reduced the possibility of its standardized application
in heterogeneous contexts. The resulting different procedures and strategies used by the centers were associated
with process outcomes. Context-specific variability and possible confounding will require rigorous procedures for
analysis of the intervention effects.
Trial registration: The trial was registered in ClinicalTrials.gov (identifier: NCT01365013). Registered on June 2011.
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Background
Type-2 diabetes (T2D) has become one of the main causes
of morbidity and early mortality in most countries. It is
expected that its prevalence will double by 2030 and that
it will become the seventh leading cause of death world-
wide [1]. Therefore, there is a growing interest in the
translation of the promising results obtained by several
clinical trials in the prevention of T2D through educa-
tional interventions to change lifestyles [2–6], into “real-
world” clinical practice conditions [7–9]. Unfortunately,
this step is not at all easy. The widespread adoption of a
promising experimental health intervention does not
automatically follow from research proving its efficacy, let
alone in the specific context of primary health care (PHC),
characterized by work overload, with shortages of time
and training. In recent years, there have been several ini-
tiatives assessing the transfer of T2D prevention interven-
tions involving the promotion of healthy lifestyles to the
real context of PHC [7–10]. However, most of these stud-
ies have used non-randomized designs or no comparison
groups, were not set up and implemented under real-
world conditions of PHC or relied on additional resources,
and/or did not include change in the incidence of T2D
among the outcome variables. These methodological limi-
tations and mixed results of the majority of the studies
raise doubts as to whether the implementation of such
programs in normal clinical working conditions can
achieve relevant clinical results while maintaining feasibil-
ity and sustainability [7].
The translation of evidence-based interventions into
routine clinical conditions is a complex challenge and
consequently there is a gap between what is known to
be effective and what is actually done in the course of
routine care in health systems worldwide [11]. Imple-
mentation research has emerged in the last decade as a
promising way to advance knowledge on how to inte-
grate interventions and treatments of proven efficacy,
that are not being widely and sustainably applied, into
routine clinical practice. It can be defined as the scien-
tific study of strategies to promote the systematic, wide-
spread, sustainable and continuous adoption of clinical
research findings in routine practice. In this growing
field of implementation research, one of the important
aspects considered in order to ascertain how to enhance
the effectiveness, feasibility and sustainability of inter-
ventions is their process of implementation [12]. The de-
velopment, implementation and evaluation of complex
health interventions require careful consideration of not
only outcomes obtained but also of the processes in-
volved [13, 14].
Process evaluations conducted within trials investigate
the implementation, receipt, and setting of an intervention
and help in the interpretation of the outcome results and
in ascertaining the true implications of interventions in
actual practice [14, 15]. Specifically, process evaluation re-
garding sampling, recruitment, reach and intervention
quality facilitate the interpretation of results and help to
explain discrepancies between expected and observed out-
comes [16]. Process evaluations are especially necessary in
multisite trials, where the “same” intervention may be im-
plemented and received in different ways, and conse-
quently may enable us to assess fidelity, monitor
intervention doses, and understand how context influ-
ences outcomes. This type of process data should be eval-
uated before the analysis of intervention effects since the
results of this evaluation may complete or correct the ana-
lysis. On the other hand, a better understanding of pro-
gram implementation and the barriers and facilitators
experienced may also help identify opportunities for opti-
mizing intervention delivery and may inform future im-
plementation and rollout of the intervention in other
contexts and settings, and how interventions could move
from research to practice. [14, 17]. These other types of
process data are usually collected at a later stage [16].
In 2010, the Department of Health of the Government of
the Basque Country launched the “Strategy for Tackling the
Challenge of Chronicity in the Basque Country” [18].
Among other initiatives, this department commissioned a
pilot study of the implementation of a primary program for
the prevention of T2D in 14 primary care centers of the
Basque Health Service (Osakidetza). Additionally, it funded
an independent assessment of the results to provide a basis
for future rollout of the program to the other primary care
health centers as a new approach to the prevention of T2D
in the Basque Country. The Prevention of Diabetes in
Euskadi (PreDE) project aims to perform the aforemen-
tioned independent evaluation and its primary scientific ob-
jective is to assess the effectiveness and feasibility of a T2D
prevention intervention involving the promotion of healthy
lifestyles in patients who are at high risk of developing the
disease, under normal working conditions in primary care
in Osakidetza, using an experimental a phase IV clinical
trial design [19]. The present study refers to a preliminary
process evaluation of the PreDE project. The main objec-
tives of the study are: (1) to document the content of the
intervention program actually executed to prevent T2D in
the collaborating centers following the use of a classical
passive implementation strategy, and to analyze the process
indicators of their implementation in the routine context of
PHC, and (2) to describe findings related to clinician adop-
tion, patient recruitment, exposure to intervention compo-
nents and patient baseline characteristics that will help with
the interpretation of the PreDE clinical trial results.
Methods
Study design and setting
This is an observational descriptive process study of the
2.5-year commissioned implementation of a T2D primary
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prevention program in 14 PHC centers in Osakidetza that
are participating in the PreDE cluster randomized trial
(ClinicalTrials.gov NCT01365013). The participating 14
primary care centers were randomly assigned to the inter-
vention or control groups. The PreDE research study was
reviewed and approved by the Basque Country Clinical
Research Ethics Committee (Ref: 10/2010). Our health
service provides universal coverage that is free at the point
of use, aside from co-payment for drugs, funded through
regional general taxation. Each citizen is included on the
list of one family physician or pediatrician who offers
comprehensive primary care and constitutes the gate-
keeper for referral to hospital services. Primary care pro-
fessionals work in full-time PHC teams, including family
physicians, pediatricians, nurses, and administrative staff
based at local centers providing access to health care for
users in a defined geographical area.
Eligibility and recruitment
Non-diabetic patients aged between 45 and 70 years old,
who were identified as being at high risk of developing
T2D, were eligible for study inclusion in each of the two
centers selected by convenience in the seven regions in
which the Basque Health Service is organized [19]. The
same system for identifying high-risk patients was set up
in all the centers, based on the administration of the
eight-item Spanish version of the validated Finnish
Diabetes Risk Score (FINDRISC) questionnaire [20]. All
PHC service users aged between 45 and 70 years who
attended one of the participating health centers for any
reason during the recruitment period of the program
were potential targets for the administration of the FIN-
DRISC questionnaire. Subsequently, all patients detected
as having a high risk (FINDRISC score ≥14) were invited
to participate and given a patient information sheet. Ex-
clusion criteria for being invited to enroll were doing
regular vigorous exercise, or having known diabetes or
any other chronic disease that made survival at 6 years
unlikely, any condition that could interfere with the me-
tabolism of glucose, or severe cognitive impairment. In
all cases, the information sheet explained that they were
going to be followed-up for a period of 24 months with
annual medical check-ups consisting of blood lipid pro-
file and glucose tolerance tests. In addition, for patients
at intervention centers, it provided information on the
intervention protocol. Informed consent was obtained
from each patient who agreed to participate. Next, they
were referred for an oral glucose tolerance test (OGTT)
with 75 g of glucose in accordance with the World
Health Organization guidelines and assessment of lipid
profiles and glycated hemoglobin (HbA1C) levels.
Patients who after the test were diagnosed with T2D
were seen by their family physician and excluded from
the study. At this stage, in the control health centers,
high-risk patients with glucose levels below 200 mg/ml
in the OGTT at the baseline assessments were included,
while in the intervention health centers, patients were
included if they obtained these results in the baseline
assessments and also agreed to participate in the new
educational intervention.
Intervention standardization
Primary care nursing professionals from the seven inter-
vention centers implemented the DE-PLAN (Diabetes in
Europe – Prevention using Lifestyle, Physical Activity
and Nutritional-intervention) educational intervention
program, while those in the seven control health centers
provided usual care for the prevention and treatment of
T2D based on the current clinical practice guidelines of
Osakidetza. The DE-PLAN program for promoting
healthy lifestyles (mainly diet and physical exercise) has
two phases: (1) phase 1 consists of intensive intervention
through educational sessions in small groups to encourage
the abandonment of unhealthy habits and the adoption of
healthy habits. Specifically, nurses run four 1.5-hour group
sessions. Their objective is to motivate participants to
adopt healthy lifestyle habits and to provide information
concerning suitable diets and exercise, as well as agree on
specific objectives for eating habits and physical activity,
(2) phase 2 consists of continuous reinforcement for
maintaining motivation through regular contact with
participants. Once the intensive education intervention
program has been completed, the participants regularly
(at least once every 6 weeks) receive reinforcing educa-
tional information mainly via telephone calls from nurses
through a health communication platform.
Implementation strategy
The commissioned implementation strategy to adapt the
intervention program to the setting and normal working
conditions in the health centers in our health service con-
sisted only in classical passive strategies of dissemination
such as training and provision of resources (a screening
tool embedded in the electronic health record system and
educational materials to support educational sessions).
The nurses in charge of the intervention group received a
14-hour training course focused on the content and pro-
cedures for the educational intervention. Additionally,
they received a 5-hour training course on the procedures
for screening and identifying patients, and this was also
provided to nurses of the control group centers given that
the system for screening and identifying patients was the
same in both groups.
Measurements
All data pertaining to recruitment, user demographic
characteristics (age, sex, socioeconomic status) and clinical
variables (chronic health problems, biological and clinical
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measures) are derived from data extracted from the elec-
tronic health records of Osakidetza. These data were
encrypted and managed centrally, together with other
measures to safeguard their anonymity and confidentiality,
in accordance with the General Law on Data Protection
and Patient Autonomy Law of the Spanish Government.
Coordination and quality control of the process and exe-
cution of the study was the responsibility of the Primary
Care Research Unit of Bizkaia in conjunction with the In-
formatics Department of Osakidetza.
The process and procedures for recruiting eligible
patients among those attending the PHC centers was
thoroughly assessed and described for both interven-
tion arms, as was the intervention delivery process
within the intervention centers. A program interven-
tion matrix was designed for centers to describe the
specific procedures (how, when, where), personnel and
resources involved for each of the following
intervention-related actions: screening of T2D risk
among those who attended the center aged between 45
to 70 years, presentation of the informed consent and
proposition for participation, baseline clinical testing,
annual clinical testing follow-up and educational inter-
vention organizational arrangements and performance.
This matrix was sent to and fulfilled by health care
professionals before fieldwork period finished and
returned to the research team. Doubts were resolved
by phone interview with health care professionals.
In order to help the interpretation of process results re-
garding the impact of the program’s translation to the real-
world context of PHC, we used the Reach, Efficacy, Adop-
tion, Implementation, Maintenance (RE-AIM) framework
[21] for evaluating the effectiveness and transferability of
health behavior programs in terms of public health signifi-
cance. This framework states that assessment of the public
health impact of programs requires more than efficacy test-
ing. Programs must reach a diverse and representative sam-
ple of the population at risk. They must be realistic to
adopt in specific practice/clinical settings and must be able
to be implemented as planned. Lastly, programs must also
be maintained over time in a sustainable way by the indi-
vidual and the practice/clinical setting. Taken together these
dimensions determine the overall impact of a program at
the population level. Specifically, the indicators for each of
the RE-AIM dimensions as they relate to the present
process evaluation are:
Adoption (Practice/Center level):
A1– Program participation by clinicians: proportion of
family physicians and nurses from the total staff that
accepted to participate and have actively collaborated
in the program execution.
Reach (Patient level): exposure of patients to the
program at each center:
R1– Reach of the screening procedure among
potential patients: proportion of the 45- to 70-year-old
non-diabetic patients who attended the center at least
once during the program’s recruitment period who had
their risk of developing T2D assessed.
R2– Reach of the intervention program among eligible
patients: proportion of the 45- to 70-year-old non-
diabetic patients attending the center during the
program’s recruitment period and identified as having
high risk of developing T2D who then received at least
one intervention component (included patients).
Additionally, differences in refusal and inclusion rates
and characteristics of those exposed to the intervention
and control programs were assessed and described at
group and center-within-group levels. Patient biological
and clinical variables included weight, body mass index,
cholesterol, glucose, triglyceride and blood pressure levels,
and tobacco use. Level of multimorbidity was character-
ized in terms of the number of chronic health problems
coexisting (from none to four or more) in the same pa-
tient, and was assessed by reviewing data for a 4-year
period in patient clinical records and applying a list of 52
diseases and specific criteria to consider each disease ac-
tive, based on previous work related to the burden of
chronic conditions in the Basque Country [22–24].
We also evaluated variability in the main process indica-
tors related to program exposure at group and center
levels (e.g., study participation refusal rates among those
identified as being at high risk) and the impact of recruit-
ment procedures or strategies used on these indicators.
Implementation (Patient level): reception of interven-
tion components as intended:
I1: Attendance of included patients to intensive
educational sessions. Description of the attendance of
included patients (proportion of patients attending) for
each of the different educational sessions and formats
(group, individual and/or mixed intervention).
I2: Proportion of included patients completing the
intensive educational intervention. Proportion of
included patients who attended all four programmed
educational sessions.
I3: Reception of remote interventions for continuous
reinforcement. Proportion of patients who received
remote support, having been contacted at least once or
three or more times, mainly through telephone calls or
by email.
Statistical analyses
Frequencies and the proportions were calculated for each
of the process indicators. Means and proportions were
used to describe patient characteristics for continuous and
categorical variables respectively. One-way analysis of
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variance and chi-squared tests were conducted to deter-
mine differences in patient variables at baseline. Logistic
regression was used (SAS PROC REG ver. 9.2, SAS
Institute, Cary, NC, USA, 2009) to examine the relation of
the different implemented strategies and procedures for
recruitment and intervention program organization with
process indicators related to program exposure. The stat-
istical model for testing the association of implemented
strategies and obtained reach included as covariates
patient-level variables (age, sex, co-morbidity), and center-
level variables (percentage of family physicians and nurses
adopting the program), whereas models for the rest of the
recruitment process indicators (efficiency of the screening
for detecting at risk patients; refusal rate) and for the
intervention completion indicator also included body
mass index within patient-level variables. In order to ac-
count for and test a center variability effect, previous
models were extended to generalized random effect
models with a random effect at center level (SAS PROC
GLIMMIX). This test was also performed to determine
and adjust for variability due to center in the group
baseline differences in patient variables
Results
Adoption among health care professionals
Overall, in the seven intervention centers, only 28 from
a total of 89 (31.4 %) family physician staff accepted and
actively collaborated in the study, while this figure was
49 from a total of 85 (57.6 %) for practice nurse staff
(Fig. 1). In the control centers, 43 from 100 of family
physician staff and 64 from a total of 93 (68.8 %) prac-
tice nurse staff actively collaborated. A high variability in
participation rate can be observed at center level. Less
than the half of physicians collaborated in four of the
Fig. 1 Flow of participant recruitment
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intervention centers and in four of the control centers.
The lowest participation rate of nurses in the interven-
tion centers was 25 %, yet in five of them more than the
half of nurses collaborated.
Program implementation procedures
Additional file 1 (see Additional file 1. Table outlining the
procedures and strategies used by each center) sets out the
specific procedures employed in centers for each
intervention-related action (screening of T2D risk, in-
formed consent and invitation to participate, clinical tests,
organizational arrangements and delivery of the educational
intervention). Overall, screening of T2D risk among poten-
tial patients was mainly performed by collaborating nurses
in routine or programed consultations. In some of the cen-
ters, family physicians occasionally collaborated in the
organization of screening procedures. Other procedures
used with the intention of increasing screening rates were
assessing patients when they attended the center for other
activities (wound care or tests), placing posters and paper-
based screening questionnaires in the center’s waiting
rooms, and organizing 1-day public screening in the street.
In some centers, a more specific strategy was agreed for
selecting potential patients for screening (e.g., those having
an additional risk factor such as obesity).
In the case of a patient being identified as high risk of
developing T2D, most of the collaborating centers invited
them to participate in the study and gave them informed
consent forms directly after completing the screening. In
contrast, some centers gave patients more time to reflect
and invited them for an additional consultation in which
they were asked whether they agreed to participate. Base-
line clinical testing was mostly performed in collaborating
centers, but with variations in the schedule offered (1 day
versus various days). Four of the centers were unable to
offer the blood tests and/or OGTTs and hence partici-
pants were sent to the referral hospital. Feedback on
clinical testing was given over the telephone or during in-
person appointments with the nurse or the family phys-
ician. The annual follow-up clinical testing was performed
on 2 days in most of the centers, with OGTTs and other
blood tests on one day and the rest of clinical measure-
ments (weight, blood pressure, etc.) on another.
Within the centers allocated to the intervention group,
organizational arrangements for the intervention were
mainly performed by collaborating nurses who, after agree-
ing on a timetable for the educational workshop sessions,
contacted patients by telephone. Patient preferences on the
timing of sessions were only taken into account in one of
the centers. Regarding timetable and format, most of the
centers offered patients the possibility of attending in the
morning or the afternoon and a group format, but with the
option of individual sessions on request. Two centers of-
fered only morning or only afternoon workshops, while one
of the centers offered only group-format workshops. All
centers except one ran the educational sessions in the cen-
ter itself.
Recruitment of patients among groups
Figure 1 and Table 1 present the flow diagram and the
process indicators of the recruitment and intervention de-
livery process. In short, from the 67,293 target patients aged
45 to 70 years who attended the centers during the recruit-
ment period, a total of 4170 patients were approached
through the screening of risk for T2D (FINDRISC). Within
the comparison groups, 1993 from 37,321 and 2177 from
29,972 were approached in the control and intervention
centers respectively. Thus, the reach of this screening at the
potential target population level in routine context of PC
(R1) was 5.3 % in the control group and 7.3 % in the inter-
vention group. Of those approached, 1076 (54 %) and 1052
(48.3 %) patients were identified as being at high risk of de-
veloping T2D (FINDRISC ≥14 points). When presented
with the project information sheets and informed consent
forms, 355 (33 %) and 459 (43.6 %) of the high-risk patients
refused to participate in the study while 721 and 593 were
referred for baseline OGTTs and clinical assessment in the
control and intervention centers respectively. This trans-
lates into an absolute between-group difference in partici-
pation rate of 10 %. In the statistical analysis of the
significance of this difference, considering the clustered na-
ture of data of participants within centers and a between-
cluster randomization design, the parameter estimating the
effect of the group was not significant (p = 0.27), while the
hypothesis test regarding the significance of the “center”
random effect was highly significant (p <0.001).
After performance of the baseline OGTT, 87 (11.7 %)
and 65 (10.9 %) of patients were diagnosed with un-
known diabetes with glucose levels of ≥200 mg/ml and
excluded from the study. Therefore, 634 45- to 70-
year-old non-diabetic patients who were at high risk of
developing T2D were included in the control group
centers, while in the intervention arm, 454 patients
were finally included, as 74 patients despite consenting
did not actually participate in the intervention due to
difficulties attending the sessions. Thus, after removing
the proportion of diagnosed unknown diabetes (11 %)
from those detected as being at high risk (n = 1052),
the estimated reach of the intervention program to eli-
gible 45- to 70-year-old non-diabetic patients who
were at high risk of developing T2D (R2) was 48 %.
Characteristics of included patients among groups and
centers within groups
As described in Table 2, included patients had a mean
age of 59 years, and almost two thirds were women
(62.3 %). More than a half were obese (55.5 %) and had
two or more chronic diseases (52.4 %), while 13 % were
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smokers. All measured personal and clinical characteris-
tics were balanced between groups except for sex with a
higher percentage of included patients being women in
the intervention group (66.6 % versus 58 % in the con-
trol group; P = 0.05, controlling for center variability). A
notable variability was evidenced at center level: the per-
centage of included patients who were women ranged
from 48.6 to 69.7 % and from 51.2 to 81.1 % in collabor-
ating centers in the control and intervention groups
(gender distribution in collaborating centers not shown)
respectively, this center variability being highly signifi-
cant (p <0.003).
Variability in program implementation indicators at
center level
The main recruitment process indicators varied
among collaborating centers (test for the random
effect, p <0.001). Screening reach ranged from 2.1 to
13 % in the control group, and from 2 to 20 % in the inter-
vention group. There was also considerable variation in
the efficiency of the screening procedures at finding indi-
viduals who were at high risk of developing DT2, the per-
centage of patients found to be at risk out of all those
assessed ranging from 21.8 to 80 % in the intervention
group, and from 32.4 to 70.6 % in the control group. As
previously mentioned, refusal rate varied significantly
across the collaborating health centers (p <0.001): the
lowest and highest refusal rates were 27.8 % and 58 % in
Table 2 Baseline characteristics of included patients
Control (n = 636) DE-PLAN (n = 454)
Age 59.3 (6.9) 59.3 (6.9)
% women 58.0 % 66.5 %
Weight, kg 82.9 (15.2) 80.8 (14.8)
Body mass index, kg/m2 31.0 (4.7) 31.0 (5.0)
% overweight 38.0 % 35.0 %
% obese 55.4 % 56.0 %
Cholesterol levels, mg/dL 213.7 (34.7) 217.0 (34.5)
Triglyceride levels, mg/dL 124.5 (65.9) 122.7 (60.6)
Glucose levels, mg/dL 104.6 (11.8) 104.5 (12.4)
Systolic blood pressure, mm/Hg 134.7 (15.5) 132.5 (14.3)
Diastolic blood pressure, mm/Hg 80.9 (9.6) 80.4 (8.8)
% elevated blood pressure 10.5 % 10.8 %
% smokers 13.2 % 12.6 %
Co-morbidity (%)
0 16.6 % 15.7 %
1 32.7 % 30.3 %
2 24.4 % 25 %
3 14.2 % 13.7 %
4 or more 12.1 % 15.3 %
DE-PLAN Diabetes in Europe – Prevention using Lifestyle, Physical Activity
and Nutritional-intervention







At risk of T2D OGTT performed Refusal
rate
Non- diabetic Included in study
n Total n Total n (%) n n (%) n
Intervention centers
SV 24.5 4097 256 6.2 % 158 (61.7 %) 114 27.8 % 100 (87.7 %) 77
GK 25.7 7440 282 3.8 % 212 (75.2 %) 116 44.3 % 98 (84.5 %) 82
BL 20.8 2068 296 14.3 % 116 (39.2 %) 52 55.2 % 47 (90.4 %) 39
LG 18.6 1951 391 20.0 % 125 (32.0 %) 57 54.4 % 52 (91.2 %) 51
DB 28.2 6229 125 2.0 % 100 (80.0 %) 59 41.0 % 56 (94.9 %) 54
IZ 26.1 5106 456 8.9 % 260 (57.0 %) 162 37.7 % 143 (88.3 %) 123
AR 17.6 3081 371 12.0 % 81 (21.8 %) 33 59.2 % 32 (96.7 %) 28
Total 29,972 2177 7.3 % 1052 (48.4 %) 593 43.3 % 528 (88.4 %) 454
Control centers
ZU 28.6 4632 310 6.7 % 219 (70.6 %) 176 19.6 % 146 (83.0 %) 146
LL 25.4 5041 256 5.1 % 150 (58.6 %) 106 28.7 % 93 (87.7 %) 93
TX 19.4 3928 509 13.0 % 165 (32.4 %) 82 43.0 % 78 (95.1 %) 78
AZ 25.8 3370 325 9.6 % 205 (63.1 %) 163 19.0 % 143 (87.7 %) 143
IR 14.9 6227 128 2.1 % 79 (61.7 %) 41 45.6 % 35 (85.4 %) 35
AB 22.7 5589 183 3.3 % 138 (75.4 %) 100 26.8 % 90 (90.0 %) 90
SM 26.3 8534 282 3.3 % 120 (42.6 %) 53 54.2 % 49 (92.4 %) 49
Total 37,321 1993 5.3 % 1076 (54.0 %) 721 33.0 % 634 (88.3 %) 634
T2D type-2 diabetes, FINDRISC Finnish Diabetes Risk Score, OGTT oral glucose tolerance test, PHC primary health care
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the intervention group, and 19 % and 54.2 % in the control
group.
Impact of employed procedures on process indicators
Table 3 displays the associations of strategies carried out
by centers to execute the program components and the
main process indicators related to recruitment and inter-
vention completion. Centers that used massive screening
strategies, namely, assessing potentially at-risk patients
attending the procedure/wound care room or for diag-
nostic/clinical tests, or placing posters and question-
naires in corridors and waiting rooms, tended to obtain
a higher reach but lower rates of efficiency in detecting
high-risk patients. In contrast, those centers that
employed a more specific strategy for selecting potential
patients for screening (i.e., those having an additional
risk factor such as obesity) had a lower reach but higher
efficiency rates for detecting at-risk patients out of the
total assessed. After controlling for covariates at patient
(sex, age, co-morbidity) and center (percentage of collab-
orating family physicians and nurses, center as a random
effect) levels, implementing a more specific screening
strategy was significantly associated with obtaining lower
reach rates (OR = 0.36; 95 % CI: 0.11 to 0.86), and with a
higher likelihood of obtaining a positive risk test among
patients assessed, this being 3.2-fold higher (95 % CI for
OR = 2.08 to 4.93).
Three of the strategies used were associated with re-
fusal rates. Refusal to participate in the study was twice
as likely in centers that used massive screening strategies
(OR = 2.34; 95 % CI: 1.08 to 5.07). Higher rates of refusal
to participate were also more frequent in centers in
which patients had to attend an additional consultation
to communicate their decision on whether to participate
and provide written informed consent (OR = 3.34; 95 %
CI: 1.36 to 8.21) compared to those in centers where
patients were given the informed consent form on the
same day as the screening test. In contrast, a lower re-
fusal rate was associated with use of targeted screening
based in additional risk factors (OR = 0.29; 95 % CI: 0.18
to 0.47). The effect of other strategies (e.g., blood tests
being performed outside the center) was not significantly
associated with refusal rate beyond the aforementioned
significant variability at center level.
Implementation of the intervention at patient level
As described in Table 4, 454 from a total of 528 eligible
patients (45- to 70-year-old non-diabetics who were at
high risk of developing T2D) initiated the intervention,
translating to a reach of the intervention program of
48 %. Regarding the format on the received intervention,
the majority of intervention patients (n = 418) selected
the group format, while 28 and 8 chose individual or
mixed formats respectively. Out of all included patients,
358 (78.8 % of those included in the intervention group)
completed the intervention program, attending all of the
scheduled workshop sessions (330 group format; 20 indi-
vidual format; 8 mixed format). At least three sessions
were completed by 52 patients (11.3 %), while 19 pa-
tients (4.1 %) completed two sessions and 25 (5.7 %)
completed only one session. Ongoing remote support
via telephone calls or emails was received by 91 % of
intervention patients, with 85.8 % of them receiving five
or more contacts. Lastly, regarding the organization of
the workshop sessions, offering only one timing, morn-
ing or evening, was not associated with intervention
completing rate (OR = 0.72; 95 % CI: 0.40 to 1.30), after
controlling for patient-level covariates and “center” ran-
dom effect as a source of variation.
Discussion
The present study aimed to evaluate the process indica-
tors regarding the commissioned implementation of a
T2D primary prevention intervention program in rou-
tine conditions of PHC, in order to facilitate subsequent
analysis of effects and their interpretation and to inform
future optimization of the implementation in clinical
practice. In short, the main results of this process evalu-
ation showed that the implemented strategy, primarily
based on classical passive strategies of dissemination
such as training and provision of resources, attained
modest-to-good process indicators related to adoption,
Table 3 One-way adjusted associations between implemented program procedures and strategies, and recruitment and intervention
completion process indicators
Variable Reach of the screeninga Efficiency of the screeningb Refusal rateb Completion of interventionb
Massive screening strategies 0.69 (0.19–2.50) 0.57 (0.26–1.23) 2.34 (1.08–5.07) N.A.
Targeted screening strategy 0.36 (0.11–0.86) 3.2 (2.08–4.93) 0.29 (0.18–0.47) N.A.
Additional appointment for informed consent N.A. N.A. 3.34 (1.36–8.21) N.A.
Baseline test offered on only one specific day N.A. N.A. 0.73 (0.08–6.59) N.A.
Blood test out of center N.A. N.A. 2.15 (0.81–5.75) N.A.
Intervention offered at one time of day only N.A. N.A. N.A. 0.72 (0.40–1.30)
Values are odds ratios (95 % confidence interval); N.A. not applicable, aModel 1: adjusted for patient-level variables (age, sex, co-morbidity) and center-level variables
(percentage of family physicians and nurses adopting the program) and center random effect, bModel 2: same adjustment as a, but including body mass index within
patient-level variables. Center random effect in all tested models p <0.001
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reach, and implementation of the intervention program.
However, there was evidence of a notable variability in
process indicators by center.
As underlined by the RE-AIM framework, one of the
major factors determining the potential impact of pro-
grams is that they must be appealing to health care pro-
viders and realistic to implement in practice settings. The
literature points to competing demands and lack of time
as the main reasons for refusal to participate among PHC
professionals [25]. In the present study, rates of adoption
of clinicians within centers were fair but improvable, espe-
cially among family physicians. In five out of seven centers
in each of the comparison groups, the program adoption
rate has exceeded 50 % among nurses, and only in two
centers in each of the groups was the level of collaboration
similarly high among family physicians. We are unable to
compare these adoption rates with the findings of other
studies on the translation of diabetes prevention programs
as they do not report these types of data regarding the rate
of adoption among health care professionals.
Overall, the reach of the screening procedures to iden-
tify individuals at risk of developing T2D among 45- to
70-year-old PHC users was 6.2 % (range 2 to 20 %).
Though these figures could be considered low, they
must be considered valuable as the program has been con-
ducted in the real context of primary health care delivery
process without altering usual working conditions. All pa-
tients of that age strata who attended the centers due to
any possible health complication were potential partici-
pants and were addressed by professionals after resolving
the problem that caused their attendance. Other studies
aimed at translating a T2D primary prevention program
to PHC have attained higher reach indicators ranging
from 44 to 56 %, but after conducting a previous selection
of patients from electronic health records and contacting
them by letter or telephone [26–28]. The present study
covered a much larger and broader target population than
similar translation studies of T2D primary prevention in
PHC, without a previous selection procedure of eligible
patients being carried out, thus better reproducing the
real-world conditions of PHC services. Nevertheless,
between-center variability in attained reach shows that
figures could be improved and this warrants further inves-
tigation on how to achieve a higher but tolerable reach.
Around half of the 45- to 70-year-old patients attending
PHC who were assessed were detected as having a high risk
of developing T2D (FINDRISC score ≥14), a figure within
the range previously reported in the literature [29]. How-
ever, as occurred with the reach of the screening there was
substantial within-group center variability in the efficiency
in detecting high-risk patients. Though all centers were
instructed to approach patients and screen considering only
patient age (i.e., “all patients attending the health center
aged between 45 and 70 years”), some centers targeted the
screening to high-risk patients, while others employed
more universal strategies. These different procedures af-
fected both reach rates and efficiency in detecting individ-
uals who were at high risk of developing T2D: the more
massive screening strategies had higher reach among at-
tending users but lower percentages of detection of high-
risk patients, the opposite occurring in centers that re-
stricted the screening strategy by only assessing those with
additional risk factors.
Not all the patients detected as having a high risk of de-
veloping T2D were finally included in the study. The
research-related operational and ethical requirements, and
the real-world context of PHC together with an evidenced
variability in procedures and strategies adopted between
centers, have determined two major issues that could
affect future analysis and interpretation of the program’s
effects: differences in refusal rates and in baseline compar-
ability among comparison groups. First, a higher rate of
refusal to participate in the study was encountered by col-
laborating clinicians in the intervention group centers.
This may be attributable to the fact that these patients
were not only asked to consent to the annual testing but
also were invited to attend four educational workshop ses-
sions. Second, after exclusion of a considerable proportion
Table 4 Variability in intervention-related process indicators among collaborating centers allocated to the intervention group
PHC center Intervention reacha Educational
sessions completed
Intervention format
(% group, individual, mixed)
Reception of ≥5 remote
support contacts
SV 54,7 % 96.1 % 98.7 %, 1.3 %, 0 % 94.8 %
GK 44,7 % 80.9 % 100 %, 0 %, 0 % 79.8 %
BL 36,8 % 82.5 % 89.7 %, 7.7 %, 2.6 % 77.5 %
LG 44,4 % 92.2 % 62.7 %, 37.3 %, 0 % 92.2 %
DB 56,8 % 64.8 % 90.7 %, 5.6 %, 3.7 % 81.5 %
IZ 52,8 % 66.7 % 100 %, 0 %, 0 % 86.2 %
AR 35,6 % 75.9 % 75 %, 1 %, 17.9 % 86.2 %
Total 47,9 % 78.8 % 92.1 %, 6.2 %, 1 .8 % 85.8 %
aCalculated as the proportion of patients included in the intervention from those detected as being at high risk of T2D after removing the proportion of
diagnosed unknown T2D patients in each of the centers
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of undiagnosed cases of T2D (approximately 12 % in both
groups), a higher proportion of women were included in
the intervention group, pointing to a possible selection
bias. These two sources of potential confounding would
threaten the internal validity of a phase III clinical trial
under controlled conditions [30]. In the case of a phase IV
implementation trial, aiming to conduct a broad evalu-
ation of the translation of proven efficacy interventions
into routine care, the focus should be on external validity
and generalizability, thus assessing effectiveness in hetero-
geneous, unselected populations and real-world clinical
settings [30, 31]. In any case, and taking the worst case
scenario of analyzing this clustered trial as an observa-
tional study, rigorous analytic procedures will need to be
used in the analysis of effects of this intervention in order
to reduce and deal with the possible confounding and
context-specific variability [32].
When analyzing the source of observed differences in
refusal rates and in the proportion of women included,
three important factors must be noted. First, as previ-
ously observed with the screening reach and its effi-
ciency at detecting high-risk patients, refusal rate is
associated with procedures and strategies for recruit-
ment. Specifically, centers that used massive screening
strategies and those that did not obtain patient consent to
participate directly after the screening (offering an add-
itional consultation) had higher odds of refusal. Second,
strong between-center variability was present even after
adjusting for the effect of group, these differences between
centers being at least as relevant as those observed at
group level for explaining differences in both refusal rates
and percentage of women included. Lastly, considering
that a passive implementation strategy reduces the possi-
bility of a standardized implementation of programs, leav-
ing the responsibility for program organization decision-
making to health professionals themselves, this observed
variability at center level could be expected. Variability in
program adoption by professionals among different sites
and in program reach and implementation indicators have
also been reported in other implementation trials [33, 34].
Every center has a different context and thus implementa-
tion strategies must be targeted and adapted to that spe-
cific context. Even after a hypothetical adaptation, results
and products would be context specific as changes are
common when implementing interventions in practice
settings [35]. Therefore, a lesson learned from the current
process evaluation is that context is crucial, this meaning
that, when using passive strategies for implementation, an
a priori standardized intervention would be implemented
in different ways in different settings resulting in different
process and possibly clinical outcomes [33, 36].
Evidence has clearly demonstrated that T2D can be
prevented or delayed in at-risk individuals through in-
tensive healthy lifestyle counseling [7–10]. The reach of
the intervention program of 48 % out of all the eligible
pre-diabetic patients identified can be considered as
moderate [37]. Moreover, the quality of the intervention
program implementation can be considered good, as more
than 80 % of the patients in the intervention group finally
included received all the components of the educational
intervention program. This overall program attendance rate
is within the range of other diabetes primary prevention
programs in PHC [8, 37, 38]. Again, program completion
rates varied between intervention centers but it was not as-
sociated with the flexibility in the schedules and formats of-
fered by centers.
To the best of our knowledge, this is the first study asses-
sing the main process indicators of a translation of a T2D
prevention program in the routine PHC context. However,
the present study has several limitations. First, the process
evaluation refers to 14 selected centers. Although collabor-
ating centers seem to be quite diverse, they may not be rep-
resentative of all PHC centers across our health service. In
addition, though we have described some characteristics re-
garding representativeness, in terms of PHC size and com-
position, socio-economic status of attended populations,
and so on, a lack of some other types of information re-
garding specific context characteristics may limit the inter-
pretation of results. Though the external validity of the
study could be questioned, implementation trials aim to
conduct a broad evaluation of the translation of proven effi-
cacy interventions into routine care, thus assessing results
in heterogeneous, unselected populations and real-world
clinical settings [30, 31]. Another limitation of the present
study is that it is mainly based on quantitative data. Ascer-
taining the factors behind implementation heterogeneity
from a qualitative perspective might help in the interpret-
ation of results.
Conclusion
To determine whether a health promotion program is
feasible when translated into the real-world clinical set-
ting, important information regarding the main factors
that affect external validity should be provided. The
present process evaluation study reports on the adop-
tion, reach, implementation and other process indicators
attained by a T2D primary prevention program rolled
out in PHC to determine its actual feasibility. The mod-
est rates of adoption by clinicians and reach of the po-
tential population reflect the difficulties of integrating a
new intervention within the established functioning of
care delivery in PHC. Moreover, observed variability of
indicators at health care context level also points to the
need to adapt the intervention components and their
operation to handle the competing demands of routine
health care services. A strong theoretically grounded im-
plementation strategy to enhance the adoption and exe-
cution of an evidence-based clinical intervention, rather
Sánchez et al. Trials  (2016) 17:254 Page 10 of 12
than the classical passive dissemination strategies used
within the present commissioned implementation, might
obtain better outcomes.
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